Comments on: Pfizer’s Kindler Decries His ‘Monolithic Structure’

By: Doc

Doc — Mon, 28 Jul 2008 23:03:41 +0000

There are way too many reps period. When will big pharma realize they do not need 6 reps selling the same pill to the same docs? Seems pretty obvious to most of us.

By: James R

James R — Mon, 28 Jul 2008 22:18:01 +0000

Mr. Kindler would show a lot more leadership if he would take charge in the Chantix situation. Since there is a 50/50 shot that patients will have severe reactions to this medication, he should have the intestinal fortitude to step in. Having more trials is one way to go, especially since there are already plans to use Chantix for other medical issues. Stockholders would be better served if there is an open and honest debate about this medication and it’s severe side effects. Right now, Pfizer has it’s head in the sand and it’s up to the Mr. Kindler to take charge.

By: Just A Thought

Just A Thought — Mon, 28 Jul 2008 22:04:52 +0000

Mr. Kindler and all pharma executives need to remember that they are in a health related business and until the public health is their primary concern they are not going to be well received no matter how much dough they bring in.
The sugary marketing and newly found uses for whatever they already have in production causes doubt about this industry’s moral conscience. They are coming off as an ‘anything for a buck’ entity. I don’t think talking to the public is going to change that- though lawyers are smooth.
Preemption makes them appear to not want to take responsibility for any damage they cause. They could act quickly and in a humble manner when they get AE reports, when they know their product has done damage, instead of leaving their loyal consumers in a lurch. They should go the extra mile where testing is concerned.

Somehow that last one doesn’t sound like “efficiencies in research and development”. It does however sound responsible and like the practice of a trustworthy business.

By: Jason Smith

Jason Smith — Mon, 28 Jul 2008 20:42:01 +0000

blockbuster days are over. A TRULY innovative product will get people paying anything for it. see viagra.. these me too drugs are what’s hurting.

pfizer needs to diversify and get back into consumer health. I do think they are still too large. Go to any docs waiting room and you’ll see at least 2 pfizer reps every 4 hours. each one of them is being paid minimum of 65k plus car, plus insurance, plus 401k, plus gas, plus office supplies, etc.. their managers are making 140k, their managers are making 240k. The bottom line is that pfizer has too many sales reps and needs to trim down.

By: Sam Williams

Sam Williams — Mon, 28 Jul 2008 18:33:38 +0000

All big drug compaines have an OLD outdated business model. Throw more reps and money at the problems and they will go away. Ain’t going to work, get back to one rep detailing per territory. (no more than 3 drugs) per rep.
Give them ownership and watch what happens. You have only one person to point the FINGER at. Good Luck and listen to what makes good business sense.

By: Matthew Holford

Matthew Holford — Mon, 28 Jul 2008 14:04:56 +0000

“When it comes to their health and money, a lot of people are frustrated about the prices and the fact that we make money…”

No, we’re frustrated that your product is shite, but is characterized as excellent. I suggest you try to be a little more accurate in your analysis, Jeff, and when you ask that question, next time, listen to the response.

Matt